Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Medication for Nonallergic Rhinitis Based on Cluster Analysis
NCT04002349Unknown
- Sponsor
- Beijing Tongren Hospital
- Start
- Jul 2019
- Primary completion
- Dec 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised trial of EPI-EE and levocabastine in idiopathic rhinitis (NAR) (4 arms), sponsored by Beijing Tongren Hospital. Primary endpoint: Relief of bothersome symptoms at 2 weeks. Status: unknown.
02
Drugs
EPI-EElevocabastine
03
Conditions
idiopathic rhinitis (NAR)
Beyond the preview
Go deeper on NCT04002349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04002349.